New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis
(2021)
Journal Article
Chetty, S., Armstrong, T., Sharma Kharkwal, S., Drewe, W. C., De Matteis, C. I., Evangelopoulos, D., Bhakta, S., & Thomas, N. R. (2021). New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis. Pharmaceuticals, 14(4), Article 361. https://doi.org/10.3390/ph14040361
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by... Read More about New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis.